Christopher Degnan Net Worth

The estimated Net Worth of Chris Degnan is at least $2.23 Milhão dollars as of 13 March 2023. Mr. Degnan owns over 10,000 units of Galera Therapeutics Inc stock worth over $730 and over the last 6 years he sold GRTX stock worth over $0. In addition, he makes $2,229,090 as Chief Financial Officer at Galera Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Degnan GRTX stock SEC Form 4 insiders trading

Christopher has made over 2 trades of the Galera Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of GRTX stock worth $19,600 on 13 March 2023.

The largest trade he's ever made was buying 10,000 units of Galera Therapeutics Inc stock on 13 March 2023 worth over $19,600. On average, Christopher trades about 1,625 units every 216 days since 2018. As of 13 March 2023 he still owns at least 10,000 units of Galera Therapeutics Inc stock.

You can see the complete history of Mr. Degnan stock trades at the bottom of the page.

Christopher Degnan biography

Christopher Degnan serves as Chief Financial Officer of the Company. Mr. Degnan was most recently the Chief Financial Officer at Verrica Pharmaceuticals Inc., a public, late-stage biotechnology company focused on medical dermatology, from March 2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014, where he most recently served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he was the Vice President of Finance, Chief Financial Officer for Endo’s U.S. Branded Pharmaceuticals segment. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004, most recently as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. He is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status). Mr. Degnan holds a B.B.A. degree in Accountancy from the University of Notre Dame.

What is the salary of Christopher Degnan?

As the Chief Financial Officer of Galera Therapeutics Inc, the total compensation of Christopher Degnan at Galera Therapeutics Inc is $2,229,090. There are 1 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.

How old is Christopher Degnan?

Christopher Degnan is 40, he's been the Chief Financial Officer of Galera Therapeutics Inc since 2019. There are 17 older and no younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.

What's Christopher Degnan's mailing address?

Chris's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC., P.O. BOX 134, MALVERN, PA, 19355.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ..., eBioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Complete history of Mr. Degnan stock trades at Verrica Pharmaceuticals Inc e Galera Therapeutics Inc

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO